{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:07:33Z","timestamp":1783649253896,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All-India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jpsychires.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T20:25:48Z","timestamp":1549916748000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial"],"prefix":"10.1016","volume":"112","author":[{"given":"Monalisa","family":"Jena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswa Ranjan","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santanu","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallabi","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash Ranjan","family":"Meher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4063-9178","authenticated-orcid":false,"given":"Rituparna","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2019.02.007_bib1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1586\/ern.09.152","article-title":"Neurodegeneration in schizophrenia","volume":"10","author":"Archer","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0278-5846(01)00159-2","article-title":"Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents","volume":"25","author":"Ashe","year":"2001","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00213-012-2900-0","article-title":"Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid","volume":"226","author":"Calabrese","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12325-012-0052-6","article-title":"Lurasidone in schizophrenia: new information about dosage and place in therapy","volume":"29","author":"Citrome","year":"2012","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00084-0","article-title":"Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses","volume":"52","author":"Durany","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S1461145711000150","article-title":"Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress","volume":"15","author":"Fumagalli","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/jnr.10609","article-title":"Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity","volume":"72","author":"Fumagalli","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-genom-082410-101459","article-title":"Genetics of schizophrenia: new findings and challenges","volume":"12","author":"Gejman","year":"2011","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib9","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1126\/science.7907431","article-title":"Requirement for BDNF in activity-dependent survival of cortical neurons","volume":"263","author":"Ghosh","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/YIC.0b013e328338bc5a","article-title":"Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics","volume":"25","author":"Gonzalez-Pinto","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib11","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1523\/JNEUROSCI.23-17-06856.2003","article-title":"Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites","volume":"23","author":"Gorski","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40263-015-0308-1","article-title":"A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia","volume":"30","author":"Harvey","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib13","first-page":"21","article-title":"Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients","volume":"22","author":"Hori","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1600-0447.1997.tb09654.x","article-title":"Schizophrenia and neurotrophin-3 alleles","volume":"95","author":"Jonsson","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib16","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/sj.npp.1300836","article-title":"Occupancy of striatal and extrastriatal dopamine D2\/D3 receptors by olanzapine and haloperidol","volume":"30","author":"Kessler","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2478\/folmed-2014-0003","article-title":"Brain-derived neurotrophic factor and its serum levels in schizophrenic patients","volume":"56","author":"Koeva","year":"2014","journal-title":"Folia Med. (Plovdiv)"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e31821895c1","article-title":"Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment","volume":"31","author":"Lee","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib19","first-page":"142","article-title":"BDNF and NGF signalling in early phases of psychosis: relationship with inflammation and response to antipsychotics after 1 year","volume":"42","author":"Martinez-Cengotitabengoa","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/schbul\/sbl004","article-title":"Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment","volume":"32","author":"Matza","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib21","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.neuro.22.1.295","article-title":"Neurotrophins and synaptic plasticity","volume":"22","author":"McAllister","year":"1999","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00213-012-2815-9","article-title":"Evaluation of dopamine D(2)\/D(3) and serotonin 5-HT(2)A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography","volume":"225","author":"Nakazawa","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0447.1994.tb01534.x","article-title":"Neurotrophin-3 gene polymorphism associated with schizophrenia","volume":"89","author":"Nanko","year":"1994","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib25","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s00213-014-3515-4","article-title":"Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients","volume":"231","author":"Nikolac Perkovic","year":"2014","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.pharep.2013.12.008","article-title":"The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats","volume":"66","author":"Nowakowska","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1192\/bjp.bp.110.084384","article-title":"Neurodevelopmental hypothesis of schizophrenia","volume":"198","author":"Owen","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib28","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1471-4159.2005.03135.x","article-title":"Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease","volume":"93","author":"Peng","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib29","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s11064-006-9162-3","article-title":"Possible mechanisms of neurodegeneration in schizophrenia","volume":"31","author":"Perez-Neri","year":"2006","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/mp.2016.235","article-title":"A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia","volume":"22","author":"Qin","year":"2017","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000369214","article-title":"Is schizophrenia a neurodegenerative disease? Evidence from age-related decline of brain-derived neurotrophic factor in the brains of schizophrenia patients and matched nonpsychiatric controls","volume":"15","author":"Rao","year":"2015","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neulet.2008.05.022","article-title":"Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia","volume":"439","author":"Reis","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/15622970802182733","article-title":"Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics","volume":"11","author":"Rizos","year":"2010","journal-title":"World J. Biol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib35","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.euroneuro.2014.08.009","article-title":"Equipercentile linking of scales measuring functioning and symptoms: examining the GAF, SOFAS, CGI-S, and PANSS","volume":"24","author":"Samara","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib36","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0000000000000378","article-title":"Lower brain-derived neurotropic factor levels in untreated adolescents with first-episode psychosis","volume":"35","author":"Simsek","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib37","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/schbul\/sbn117","article-title":"Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions","volume":"34","author":"van Os","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neulet.2008.04.027","article-title":"Decreased serum neurotrophin 3 in chronically medicated schizophrenic males","volume":"440","author":"Vargas","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1469-7580.2003.00203.x","article-title":"Neurotrophins and the immune system","volume":"203","author":"Vega","year":"2003","journal-title":"J. Anat."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib40","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.mp.4001308","article-title":"Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia","volume":"8","author":"Weickert","year":"2003","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib41","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.neuroscience.2010.05.037","article-title":"Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia","volume":"169","author":"Wong","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.psychres.2010.12.017","article-title":"The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia","volume":"189","author":"Xiong","year":"2011","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neulet.2013.09.059","article-title":"Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine","volume":"556","author":"Yamamori","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jpsychires.2019.02.007_bib44","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-018-4835-6","article-title":"Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2019.02.007_bib45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.psychres.2014.11.015","article-title":"The brain-derived neurotrophic factor Val66Met polymorphism is not associated with schizophrenia: an updated meta-analysis of 11,480 schizophrenia cases and 13,490 controls","volume":"225","author":"Zhao","year":"2015","journal-title":"Psychiatr. Res."}],"updated-by":[{"DOI":"10.1016\/j.jpsychires.2019.11.019","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000}}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618314614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618314614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:11:54Z","timestamp":1758366714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395618314614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":45,"alternative-id":["S0022395618314614"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2019.02.007","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}